Compare Cassava Sciences Inc (FLNA) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Charles Schwab Corporation Common Stock — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Charles Schwab Corporation Common Stock trades at $96.77 (market cap $167.52B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 4251.8× Cassava Sciences Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.32% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| FLNA | SCHW | |
|---|---|---|
Market Cap | $39.40M | $167.52B |
Volume | 759,018 | 6,554,126 |
Sector | Health | Financials |
52-Week High | $4.64 | $113.65 |
52-Week Low | $0.68 | $85.35 |
Typical Hold Time | 37 Days | 85 Days |
Enterprise Value | -$43.28M | $153.97B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.
While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.
Charles Schwab (SCHW) trades at $96.70, up 1.17% with bearish technical signals but strong fundamentals. The company reported record quarterly revenue of $7.08 billion (The Motley Fool, 2026-09-29) and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains bullish with a $120.33 price target, representing 24% upside potential. Recent developments include dual listing on the Texas Stock Exchange and AI integration partnerships with Anthropic.
SCHW offers compelling value with a P/E of 17.64 and robust 38.79% net margin, though technical indicators signal near-term caution. The stock faces risks from narrowing interest spreads and market volatility, but strong earnings momentum and institutional support provide solid foundation for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
